Humacyte Inc
NASDAQ: HUMA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-02
Humacyte Inc (HUMA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $6.19M | $-85.42M | -1,121.97% | -1,385.02% | -1,380.67% |
| 2020 | $1.49M | $-66.52M | -3,526.96% | -4,332.66% | -4,461.70% |
| 2021 | $1.26M | $-26.48M | -4,756.77% | -6,429.77% | -2,096.36% |
| 2022 | $1.56M | $-11.96M | -427.48% | -5,404.35% | -764.54% |
| 2023 | $0.00 | $-110.78M | — | — | — |
| 2024 | $0.00 | $-148.70M | — | — | — |
| 2025 | $2.04M | $-40.83M | -736.46% | -5,271.69% | -2,003.58% |
Frequently asked questions
What is Humacyte Inc's revenue?
Humacyte Inc's trailing twelve-month revenue is $2.02M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is HUMA?
In its most recent fiscal year, HUMA ran a gross margin of -736.46%, an operating margin of -5,271.69%, and a net margin of -2,003.58%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does HUMA generate?
HUMA produced $-105.93M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is HUMA's balance sheet healthy?
HUMA holds $50.50M in cash and equivalents against $35.44M in long-term debt, on $3.11M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.